Goa facility receives EIR from USFDA: Cipla

New Delhi: Pharma major Cipla Thursday said it has received an establishment inspection report(EIR) from the US health regulator after inspection of its Goa facility.

Confirmation to this effect was given by the company in a BSE filing.

The United States Food and Drug Administration (USFDA) has carried the inspection at the Goa manufacturing facility from 21-28 January 2019.

Thereafter, the company received an EIR, indicating closure of the inspection, it added.

Also Read: Cipla signs over Rs 152 crore pact with Pulmatrix for new asthma drug Pulmazole

Headquartered in Mumbai, the pharmaceutical and biotechnology firm primarily develope medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.